

Applicants : Peter Brink et al.  
Serial No. : 10/757,827  
Filed : January 15, 2004  
Page 3

claims be examined in this application.

The Examiner has also stated that claims 1, 4, 8, 12, 16, 20, 23, 27, 31 and 35 recite a plurality of patentably distinct sequences: HCN1, HCN2, HCN4, E324A-HCN2, Y331A-HCN2 and Y331A-E324A-HCN2, and requires us to elect one sequence. In response, applicant elects HCN2.

The Examiner also states that the claims are directed to the following patentably distinct species of the claimed invention: pacemaker current and cardiac rhythm disorder, and requires us to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 51 is generic. In response, applicant elects pacemaker current.

The Examiner also stated that claims 41-48 are generic to a plurality of disclosed patentably distinct species comprising: heart, bladder, artery, arteriole, liver, gastrointestinal tract, tumor originating from epithelial tissue and tumor originating from smooth muscle cells, and requires us to elect a single disclosed species, even though this requirement is traversed. In response, applicant elects the heart.

The Examiner also stated that claims 57-62 are generic to a plurality of disclosed patentably distinct species comprising: inducing current in heart, increasing heart rate, inducing current in the cell, contraction of the cell, shortening the time required to activate cells and changing membrane potential of the cell, and requires us to elect a single disclosed species, even though this requirement is traversed. In response, applicant elects inducing current in heart.

Applicants : Peter Brink et al.  
Serial No. : 10/757,827  
Filed : January 15, 2004  
Page 4

The Examiner also states that the claims are directed to the following patentably distinct species of the claimed invention: conduction block, complete atrioventricular block, incomplete atrioventricular block and sinus node dysfunction, and requires us to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 54 is generic. In response, applicant elects incomplete atrioventricular block.

The Examiner also states that the claims are directed to the following patentably distinct species of the claimed invention: topical application structure, microinjection and catheterization, and requires applicant to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 55 is generic. In response, applicant elects microinjection.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is


Applicants : Peter Brink et al.  
Serial No. : 10/757,827  
Filed : January 15, 2004  
Page 5


hereby given to charge the amount of any such fee to Deposit  
Account 03-3125.

Respectfully submitted,

I hereby certify that this correspondence  
is being deposited this date with the  
U.S. Postal Service with sufficient  
postage as first class mail in an  
envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

 10/21/05  
Peter J. Phillips Date  
Reg. No. 29,691

  
John P. White  
Registration No. 28,678  
Peter J. Phillips  
Registration No. 29,691  
Attorney for Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400